BioNTech SE is 3.4x more valuable than Kymera Therapeutics, Inc. by market capitalization ($21.79 B vs $6.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | BNTX |
|---|---|---|
| Market cap | $6.44 B | $21.79 B |
| US-listed rank | #1211 | #587 |
| Revenue (latest FY) | $39.21M | - |
| Net income (latest FY) | $311.35M | - |
| Net margin | 794.0% | - |
| P/E (trailing FY) | 20.7 | - |
| SEC filings | 575 | 548 |
BioNTech SE is 3.4x more valuable than Kymera Therapeutics, Inc. by market capitalization ($21.79 B vs $6.44 B).
Full pages: Kymera Therapeutics, Inc. and BioNTech SE, or browse the full rankings.